Shasun Chemicals & Drugs Ltd., a leading Indian CRAMS and API exporting pharmaceutical company, today announced the company’s financial results for the quarter ended September 30, 2008. For Q2 FY09, the company posted revenues of Rs. 127 crore, a growth of 5 per cent compared to Q2 FY08. Due to the steep depreciation of the Rupee against the US Dollar, the company suffered forex losses of Rs. 13.50 crore (against Rs. 10.25 crore gain for Q2 last year) resulting in Net Loss of Rs.10.71 crore as against Net Profit of Rs 6.89 crore for the corresponding quarter of last year.
On a consolidated basis, revenues for the quarter stood at Rs 219 crore compared to Rs 206 crore for Q2FY08, registering a growth of 6%. The Net Loss of the period stood at Rs. 19.04 crores as against Net Profit of Rs. 8.2 crore for the corresponding quarter of previous year.
Update on UK subsidiary company
Following a detailed and comprehensive review of customer demands and activity levels the Company has reached a decision that the Annan facility is no longer a viable facility and will be closed by end March 2009. Products manufactured at the Annan site would be relocated to alternative Shasun locations. The cost of restructuring would be met out of operating cash flow of Shasun Pharma Solutions Ltd. UK.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
